Sanofi: France’s Pharma Giant and the Dupixent Engine

Sanofi is betting its future on a simple, ruthless idea: be great at inventing medicines, and shed everything else. Around a single mega-blockbuster and a world-class vaccines business, it is reshaping itself into a pure science-driven biopharma. This article explains how Sanofi makes money, why one drug matters so much, and why it is selling a profitable business to sharpen its focus.

The transformation carries real stakes for France and Europe, where Sanofi is a strategic industrial asset and a symbol of the continent’s ability to compete with American and Chinese pharma. How successfully it reinvents itself as a focused innovator is therefore watched far beyond its own shareholders.

What is Sanofi and what does it do?

Sanofi is a French multinational and one of the world’s largest pharmaceutical companies, discovering, developing, manufacturing and selling prescription medicines and vaccines. Its business has three parts: innovative medicines (its core, spanning immunology, oncology, rare diseases and more), a leading global vaccines division, and a consumer-healthcare arm, Opella, which it is in the process of divesting.

In 2024 Sanofi generated around €41 billion in sales, with the immunology drug Dupixent its single biggest earner. It employs roughly 90,000 people, sells its products in most countries on earth, and stands as a pillar of the French and European life-sciences industry, with its headquarters in Paris.

Sanofi’s identity is shifting decisively toward being a ‘biopharma’ — a company focused on innovative, science-heavy prescription medicines and vaccines, rather than a sprawling healthcare conglomerate. Understanding that transformation, and the blockbuster economics behind it, is the key to understanding the company.

Why does one drug, Dupixent, matter so much?

Dupixent, an immunology medicine co-developed with the US biotech Regeneron, is the engine of Sanofi’s growth, generating roughly €13 billion in 2024 sales and still expanding fast. It treats a widening range of inflammatory conditions — eczema (atopic dermatitis), asthma, nasal polyps and, newly, chronic obstructive pulmonary disease (COPD), where it became the first biologic treatment approved.

A single drug earning this much illustrates the blockbuster economics that define modern pharma. Because a successful medicine can be manufactured at relatively modest marginal cost once developed, and sells at high prices to large patient populations, its profits are enormous — and Dupixent’s expansion into new diseases keeps enlarging that population. One blockbuster can transform a company’s fortunes.

The partnership behind Dupixent is itself instructive. Sanofi shares the drug with Regeneron, meaning it does not keep every euro of that €13 billion, but the collaboration gave it access to a molecule and a science it might not have developed alone. Such alliances — splitting the risk, cost and reward of a blockbuster — are increasingly how big pharma secures its biggest products, and Dupixent is the outstanding example of one paying off handsomely.

But dependence on one product is also a vulnerability. Dupixent’s dominance means Sanofi’s growth is heavily tied to it, and the company must eventually replace it as patents expire years from now. This is why Sanofi is pouring money into research to find the next generation of medicines — the blockbuster that pays for today must be succeeded by the blockbuster of tomorrow.

How does R&D drive a pharma company?

Research and development is the lifeblood of a pharmaceutical company, and Sanofi spends heavily on it — around €7.4 billion in 2024, up sharply — because its entire future depends on inventing new medicines. Unlike most industries, pharma faces a ‘patent cliff’: drugs lose exclusivity after a period, allowing cheap generic copies that collapse their sales, so companies must constantly discover replacements.

This creates a relentless innovation treadmill. Sanofi must fund a large pipeline of experimental drugs, the great majority of which will fail in testing, in the hope that a few succeed and become the blockbusters that sustain the company for the next decade. R&D is therefore not a cost to minimise but the core investment that determines survival — the more productive the pipeline, the healthier the company’s future.

Sanofi’s pipeline includes promising candidates in multiple sclerosis (tolebrutinib), rare diseases (rilzabrutinib) and oncology (Sarclisa), among others. The strategic bet is that concentrating resources, talent and management attention on this innovative pipeline — rather than diluting them across unrelated businesses — will make Sanofi’s R&D more productive and its growth more durable. This focus on invention is what distinguishes a modern biopharma from a diversified health conglomerate.

Why is Sanofi selling its consumer-health business?

Sanofi is selling a controlling stake in Opella, its consumer-healthcare arm (maker of over-the-counter products like the painkiller Doliprane and various wellness brands), to the private-equity firm CD&R, in order to become a ‘pure-play’ innovative-medicines and vaccines company. It is a deliberate act of strategic focus.

The logic is that consumer health and innovative pharma are fundamentally different businesses. Selling branded painkillers and supplements is a marketing-driven, steady, lower-risk business, while inventing prescription medicines is a high-risk, science-driven, high-reward one. Run together, each distracts from the other and neither gets full focus; separated, each can be managed and valued on its own terms.

By divesting Opella, Sanofi frees management attention and capital to concentrate entirely on its R&D-driven core, and and raises substantial proceeds it can reinvest in its pipeline or in acquisitions. It is the same ‘focus on what you do best’ logic seen across the France Company Stories hub — from Sodexo’s Pluxee spin-off to Danone’s portfolio pruning — applied to one of Europe’s largest drugmakers.

How does Sanofi use acquisitions to grow?

Alongside its own laboratories, Sanofi increasingly uses acquisitions and licensing deals to fill and refresh its pipeline — a strategy known as ‘external innovation.’ With a strong balance sheet, boosted by the Opella sale, it can buy promising biotech companies or license their experimental drugs to add new medicines faster than internal research alone would allow.

This reflects a wider truth about modern pharma: much of the most exciting early-stage science now happens in small, specialised biotech firms, and large companies like Sanofi act partly as developers, financiers and distributors that scale those discoveries up. Sanofi’s management has signalled it will pursue deals opportunistically — ‘without pressure,’ as its executives put it — to strengthen its pipeline rather than chase size for its own sake. Balancing internal R&D with well-chosen acquisitions is central to keeping the innovation engine full, and it is a discipline shared with specialty peers elsewhere in this pillar.

Why is the vaccines business so valuable?

Sanofi is one of the world’s leading vaccine makers, and this business is a valuable, somewhat separate pillar of the company. Vaccines are a high-barrier business — complex to develop and manufacture, requiring specialised facilities and expertise that few companies possess — which protects established players like Sanofi from easy competition.

The division spans influenza vaccines, standard childhood immunisations, travel and endemic-disease vaccines, and newer products like Beyfortus, an antibody that protects newborns against respiratory syncytial virus (RSV), which rapidly became a significant earner within its first full seasons on the market. Vaccines provide steady, essential demand driven by public health needs, and their sheer manufacturing complexity gives Sanofi durable, hard-to-replicate competitive advantages, making the business a stable complement to the more volatile world of blockbuster medicines.

Vaccines also carry strategic and reputational weight beyond their revenue. As the world learned during recent pandemics, the ability to develop and mass-produce vaccines is a matter of national and global security, and governments value manufacturers who can deliver at scale in a crisis. For Sanofi, leadership in vaccines is thus both a solid commercial business and a source of standing with the public authorities that regulate and purchase its products worldwide.

What are the risks facing Sanofi?

Sanofi’s central risk is its heavy dependence on Dupixent: any setback to that drug, or the challenge of eventually replacing its revenue when patents expire, would hit the company hard. More broadly, it faces the perpetual pharma risk of R&D failure — expensive drug candidates that flop in trials — and the patent cliffs that erode older products.

It also operates under intense regulatory scrutiny, drug-pricing pressure from governments and insurers (especially in the United States, its largest market), competition from rival drugmakers and cheaper biosimilar copies, and the execution risk of its transformation. Divesting Opella removes a stable earnings cushion, raising Sanofi’s exposure to the ups and downs of its innovative pipeline. Litigation risk, always present in the pharmaceutical industry, adds a further layer of uncertainty.

What can founders learn from Sanofi?

Sanofi teaches the economics of innovation-driven businesses, where enormous, high-risk investment in R&D is the price of admission and a single breakthrough can pay for everything. It shows how blockbuster products transform a company — and why the relentless pursuit of the next breakthrough, through a deep pipeline, is a matter of survival rather than ambition.

It also demonstrates the power of strategic focus: Sanofi’s decision to shed a profitable consumer-health business to concentrate on innovative medicines reflects a conviction that doing one hard thing exceptionally well beats doing several things adequately. For anyone studying the France Company Stories hub, Sanofi is the case study in R&D-driven value creation and disciplined focus — proof that in science-based industries, the courage to concentrate on your core capability is itself a strategy. Explore the diagnostics, eyewear and cosmetics champions around it across the Pharma, Health & Cosmetics pillar.

Frequently Asked Questions